Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

Investigational New Drugs
A Craig LockhartAfshin Dowlati

Abstract

Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclitaxel (arm 2, n = 26), or gemcitabine (arm 3, n = 10) in 21-days (arms 1 and 2) or 28-days (arm 3) cycles. A lead-in cohort (arm 2a, n = 6) determined the arm 2 carboplatin dose. Dose escalation proceeded via continual modified reassessment. Results Pevonedistat MTD was 25 mg/m2 (arm 1) or 20 mg/m2 (arm 2); arm 3 was discontinued due to poor tolerability. Fifteen (23%) patients experienced dose-limiting toxicities during cycle 1 (grade ≥3 liver enzyme elevations, febrile neutropenia, and thrombocytopenia), managed with dose holds or reductions. Drug-related adverse events (AEs) occurred in 95% of patients. Most common AEs included fatigue (56%) and nausea (50%). One drug-related death occurred in arm 3 (febrile neutropenia). Pevonedistat exposure increased when co-administered with carboplatin plus paclitaxel; no obvious changes were observed when co-administered with docetaxel or gemcitabine. Among 54 response-evaluable patients, two...Continue Reading

References

Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J TaberneroJ Baselga
Sep 8, 2006·The New England Journal of Medicine·Ken A OlaussenUNKNOWN IALT Bio Investigators
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Teresa A SoucyMark Rolfe
Jun 15, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sufeng ChenHaiquan Chen
Nov 16, 2012·Current Pharmaceutical Design·Yongchao Zhao, Yi Sun
Mar 22, 2013·The New England Journal of Medicine·Luc FribouletJean-Charles Soria
May 2, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steffan T NawrockiJennifer S Carew
May 21, 2013·DNA Repair·Teruaki Iyama, David M Wilson
Mar 8, 2014·Scientific Reports·David Hersi SmithSussie Steen Jensen
May 24, 2014·Journal of the National Cancer Institute·Lihui LiLijun Jia
Oct 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John SarantopoulosR Donald Harvey
Nov 13, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jatin J ShahSagar Lonial

❮ Previous
Next ❯

Citations

Mar 12, 2019·Current Topics in Medicinal Chemistry·Lina YinQingzhong Hu
Jan 18, 2020·Journal of Clinical Medicine·Vincent Turon-LagotEloi R Verrier
Feb 16, 2020·Cancers·Rishil J KathawalaSteffan T Nawrocki
Jun 19, 2020·Cancers·Ainsley Mike AntaoSuresh Ramakrishna
Mar 8, 2019·British Journal of Clinical Pharmacology·Hélène FaesselR Donald Harvey
Jun 9, 2020·Acta Biochimica Et Biophysica Sinica·Yilin Chen, Jianping Jin
May 3, 2019·International Journal of Cancer. Journal International Du Cancer·Shaolong ZhouXinjun Wang
Jul 12, 2019·Frontiers in Immunology·Guangqing YuWuhan Xiao
Feb 20, 2020·Cell & Bioscience·Jia YuZhenkun Lou
Dec 4, 2019·Nature Reviews. Clinical Oncology·Joseph A ClaraNaoko Takebe
Nov 4, 2020·International Journal of Molecular Sciences·Roya RasaeiSeok-Ho Hong
Nov 13, 2020·Pharmacological Reviews·Samir H Barghout, Aaron D Schimmer
Feb 18, 2021·Annals of the New York Academy of Sciences·Jichuan WangBang H Hoang
Apr 4, 2021·International Journal of Molecular Sciences·Alena MickovaJan Bouchal
May 22, 2021·Genes & Development·Justin P NortonDavid MacPherson
Jul 2, 2021·Frontiers in Oncology·Zeyaul IslamPrasanna R Kolatkar
Jul 30, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Laiqing XieManhui Zhu
Sep 4, 2021·Journal of Biochemical and Molecular Toxicology·Yousra M El-Far, Mohamed El-Mesery

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Clinical Trials Mentioned

NCT01814826
NCT02610777
NCT03268954
NCT01862328
NCT03057366

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.